Endocrinology, Vol 128, 1687-1692, Copyright © 1991 by Endocrine Society

ARTICLES

On the mechanisms for the selective action of vitamin D analogs

AS Dusso, L Negrea, S Gunawardhana, S Lopez-Hilker, J Finch, T Mori, Y Nishii, E Slatopolsky and AJ Brown
Department of Medicine, Washington University School of Medicine, St. Louis, Missouri 63110.

A variety of analogs of 1,25-(OH)2D3 with less calcemic activity and lower receptor binding affinity than 1,25-(OH)2D3 have been developed. However, these compounds have equal or greater ability to differentiate leukemia cells and psoriatic fibroblasts and to suppress PTH synthesis and secretion. The mechanism for this selectivity has not been elucidated. Because the lower potency of ergocalciferol compared to cholecalciferol in preventing or curing rickets in chicks was associated with a lower affinity of the avian vitamin D binding protein (DBP) for vitamin D2, we tested five analogs with low calcemic activity including 22-oxa-1,25-(OH)2D3 (OCT), MC903, 1,25-(OH)2-16 ene-23-yne D3, 1,25-(OH)2-26,27 dihomo-22-ene-D3, and 1,25-(OH)2-24-trihomo-22-ene- D3 for their affinity for rat serum DBP. All analogs had a low affinity for DBP, ranging from 50-3000 times less than that of 1,25-(OH)2D3. OCT also bound with low affinity to dog and human serum DBP. We tested with OCT the possible consequences of its low affinity for serum DBP. One of the functions of DBP is to prolong the lifetime of 1,25-(OH)2D3 in circulation. Quantification of the metabolic clearance rate (MCR) of OCT in 8 normal dogs using a single bolus injection technique showed that OCT was cleared at a rate of 48.2 +/- 7.5 ml/min, approximately 6- 7 times more rapidly than 1,25-(OH)2D3 (6.8 +/- 0.4 ml/min). The estimated half-life of OCT in the circulation was 2.5 +/- 0.3 h compared to 7.0 +/- 0.6; n = 7 for 1,25-(OH)2D3. As our primary interest is the potential of OCT in treating the secondary hyperparathyroidism of CRF, we also measured the MCR of OCT in 5/6 nephrectomized dogs. Uremia does not affect the rate of clearance of OCT from the circulation (MCR: 56.8 +/- 4.5; t1/2 = 2.1 +/- 0.2 n = 4). Despite its shorter half-life, OCT suppressed PTH secretion in vivo in uremic dogs. The effects of low binding to DBP on the percentage uremic dogs. The effects of low binding to DBP on the percentage of free sterol were determined using an ultrafiltration procedure. We compared the proportion of free (unbound) OCT and 1,25-(OH)2D3 in 0.1% BSA-PBS with concentrations of human serum ranging from 0-25%. The proportion of OCT in the free form was significantly higher than that of 1,25- (OH)2D3 for every serum concentration tested. The physiological relevance of a higher percentage of free OCT was tested in normal human macrophages.(ABSTRACT TRUNCATED AT 400 WORDS)

This article has been cited by other articles:

				Z. H. Al-oanzi, S. P. Tuck, N. Raj, J. S. Harrop, G. D. Summers, D. B. Cook, R. M. Francis, and H. K. Datta Assessment of Vitamin D Status in Male Osteoporosis Clin. Chem., February 1, 2006; 52(2): 248 - 254. [Abstract] [Full Text] [PDF]

				A. S. Dusso, A. J. Brown, and E. Slatopolsky Vitamin D Am J Physiol Renal Physiol, July 1, 2005; 289(1): F8 - F28. [Abstract] [Full Text] [PDF]

				M. Hirata, K. Katsumata, K. Endo, N. Fukushima, H. Ohkawa, and M. Fukagawa In subtotally nephrectomized rats 22-oxacalcitriol suppresses parathyroid hormone with less risk of cardiovascular calcification or deterioration of residual renal function than 1,25(OH)2 vitamin D3 Nephrol. Dial. Transplant., September 1, 2003; 18(9): 1770 - 1776. [Abstract] [Full Text] [PDF]

				M. Hirata, K. Makibayashi, K. Katsumata, K. Kusano, T. Watanabe, N. Fukushima, and T. Doi 22-Oxacalcitriol prevents progressive glomerulosclerosis without adversely affecting calcium and phosphorus metabolism in subtotally nephrectomized rats Nephrol. Dial. Transplant., December 1, 2002; 17(12): 2132 - 2137. [Abstract] [Full Text] [PDF]

				S. Peleg, M. Uskokovic, A. Ahene, B. Vickery, and Z. Avnur Cellular and Molecular Events Associated with the Bone-Protecting Activity of the Noncalcemic Vitamin D Analog Ro-26-9228 in Osteopenic Rats Endocrinology, May 1, 2002; 143(5): 1625 - 1636. [Abstract] [Full Text] [PDF]

				S. L.-S. Fan, N. J. Schroeder, M. J. Calverley, J. M. Burrin, H. L.J. Makin, and J. Cunningham Potent suppression of the parathyroid glands by hydroxylated metabolites of dihydrotachysterol2 Nephrol. Dial. Transplant., December 1, 2000; 15(12): 1943 - 1949. [Abstract] [Full Text] [PDF]

				A. J. BROWN, J. FINCH, F. TAKAHASHI, and E. SLATOPOLSKY Calcemic Activity of 19-Nor-1,25(OH)2D2 Decreases with Duration of Treatment J. Am. Soc. Nephrol., November 1, 2000; 11(11): 2088 - 2094. [Abstract] [Full Text]

				L. S. HOLLIDAY, S. L. GLUCK, E. SLATOPOLSKY, and A. J. BROWN 1,25-Dihydroxy-19-nor-vitamin D2, a Vitamin D Analog with Reduced Bone Resorbing Activity In Vitro J. Am. Soc. Nephrol., October 1, 2000; 11(10): 1857 - 1864. [Abstract] [Full Text]

				K. Ozono, M. Saito, D. Miura, T. Michigami, S. Nakajima, and S. Ishizuka Analysis of the Molecular Mechanism for the Antagonistic Action of a Novel 1alpha ,25-Dihydroxyvitamin D3 Analogue toward Vitamin D Receptor Function J. Biol. Chem., November 5, 1999; 274(45): 32376 - 32381. [Abstract] [Full Text] [PDF]

				M. Kajikawa, H. Ishida, S. Fujimoto, E. Mukai, M. Nishimura, J. Fujita, Y. Tsuura, Y. Okamoto, A. W. Norman, and Y. Seino An Insulinotropic Effect of Vitamin D Analog with Increasing Intracellular Ca2+ Concentration in Pancreatic {beta}-Cells through Nongenomic Signal Transduction Endocrinology, October 1, 1999; 140(10): 4706 - 4712. [Abstract] [Full Text]

				A. J. Brown, A. Dusso, and E. Slatopolsky Vitamin D Am J Physiol Renal Physiol, August 1, 1999; 277(2): F157 - F175. [Abstract] [Full Text] [PDF]

				N. Koike, N. Hayakawa, K. Kumaki, and W. E. Stumpf In Vivo Dose-related Receptor Binding of the Vitamin D Analogue [3H]-1,25-dihydroxy-22-oxavitamin D3 (OCT) in Rat Parathyroid, Kidney Distal and Proximal Tubules, Duodenum, and Skin, Studied by Quantitative Receptor Autoradiography J. Histochem. Cytochem., December 1, 1998; 46(12): 1351 - 1358. [Abstract] [Full Text]

				G. JONES, S. A. STRUGNELL, and H. F. DeLUCA Current Understanding of the Molecular Actions of Vitamin D Physiol Rev, October 1, 1998; 78(4): 1193 - 1231. [Abstract] [Full Text] [PDF]

				S. Masuda, V. Byford, R. Kremer, H. L. J. Makin, N. Kubodera, Y. Nishii, A. Okazaki, T. Okano, T. Kobayashi, and G. Jones In Vitro Metabolism of the Vitamin D Analog, 22-Oxacalcitriol, Using Cultured Osteosarcoma, Hepatoma, and Keratinocyte Cell Lines J. Biol. Chem., April 12, 1996; 271(15): 8700 - 8708. [Abstract] [Full Text] [PDF]